In addition, it has been shown that PARP-1 inhibition may augment cisplatin cytotoxicity in cervical cancer cells by diminishing DNA repair and suppressing β-catenin signaling pathway [35]. This evidence concerns the gene PARP1 and cervical carcinoma.